Day: March 19, 2024

Achieves 15% Recurring Revenue Growth and Profitability in Q4 OTTAWA, March 19, 2024 (GLOBE NEWSWIRE) — TrueContext Corporation (TSXV: TCXT), (“TrueContext” or the “Company”) the global leader in field intelligence, announced today its annual and fourth quarter (Q4) financial results for the period ended December 31, 2023. All amounts are in US dollars unless otherwise stated. Achievements in the 2023 financial year include strong overall growth in recurring revenue combined with attainment of profitability in Q3 and $570,000 of operating income in Q4. TrueContext recently announced the signing of a definitive agreement relating to an all-cash acquisition by Battery Ventures. In light of this announcement, the Company will forego its quarterly earnings call-in connection with these results. Financial Highlights – 2023 Year (All...

PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET. A replay of the event will be available on the “Events & Presentations” page in the “Investors” section of the Company’s website at https://investors.centurytx.com/events-and-presentations and will be available for 90 days following the event. About Century Therapeutics Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products...

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the first patient has been dosed in the PARADIGM Phase 3 trial of solriamfetol, an investigational treatment for major depressive disorder (MDD). PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of MDD in adults. Approximately 300 patients will be randomized in a 1:1 ratio to receive solriamfetol (300 mg) or placebo for 6 weeks. The primary endpoint will be change in the Montgomery Åsberg Depression Rating Scale...

VANCOUVER, British Columbia, March 19, 2024 (GLOBE NEWSWIRE) — Apollo Silver Corp. (“Apollo” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to announce that it has received its Conditional Temporary Use Permit (the “Drill Permit”) from the County of San Bernardino (“the County”) authorizing 2024 drilling activities at the Waterloo Silver-Barite Property. Results from the 2024 assay testing program have been received and are being used to define planned barite assaying as part of declaring a maiden barite resource estimate at Waterloo. HIGHLIGHTS2024 Drill Permit for the Waterloo Property received from the County; and Barite analysis test program completed. Results will be incorporated into preparation for maiden barite resource estimate at Waterloo.“The receipt of the 2024 Drill Permit ensures we can...

GRASSY MOUNTAIN ENTERS FINAL PHASE OF PERMITTING WINNEMUCCA, Nev., March 19, 2024 (GLOBE NEWSWIRE) — Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) is pleased to announce that the Bureau of Land Management (“BLM”) has filed the Notice of Intent (the “Notice” or “NOI”) in the Federal Registry, thereby initiating the preparation of an Environmental Impact Statement (“EIS”) in compliance with the National Environmental Policy Act (“NEPA”) process for the proposed Grassy Mountain mine. Paramount’s President & COO, Glen van Treek, stated, “The filing of the NOI in the federal registry marks a major milestone, providing a definitive path forward towards the construction and operation of the Grassy Mountain mine. The development of Grassy Mountain offers significant potential to provide much-needed...

$2.7M cash investments secured including $0.4M from Insiders$3.75M of Debt convertedBOUCHERVILLE, Quebec, March 19, 2024 (GLOBE NEWSWIRE) — LSL PHARMA GROUP INC. (TSXV: LSL) (the “Corporation” or “LSL Pharma“), a Canadian integrated pharmaceutical company, today announced the closing on March 18, 2024 of non-brokered private placements for $6.44 million representing the first closing of the $8.0 million combined financings announced on March 7, 2024 (the “Financing”). Pursuant to the Financing, the Corporation has issued 16,086,893 units (the “Units”) at a price of $0.40 per unit for aggregate gross proceeds of $6,434,758. Each Unit consists of one class A share of the Corporation (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder, subject to adjustments...

Rego Payment Architectures, Inc, secures an extension until March 13, 2025 for its $20 million investor line of credit paving the way for expansion of its Banking-as-a-Platform offering to community and global financial institutions BLUE BELL, Pa., March 19, 2024 (GLOBE NEWSWIRE) — Rego Payment Architectures, Inc. (“REGO”) (OTCQB: RPMT), today announced it has secured an amendment to its $20 million line of credit (“LOC”) from one of its major investors, Mr. James Davison. This amendment extends the LOC until March 13, 2025. Peter S. Pelullo, Chief Executive Officer at REGO, said, “This extension positions and solidifies the company’s ability to execute our strategic planning activities for 2024. With access to this LOC, the company will have raised approximately $120 million for the development and commercialization of a ‘best-in-breed,’...